Please login to the form below

Not currently logged in
Email:
Password:

sexual dysfunction

This page shows the latest sexual dysfunction news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Sprout Pharma's 'female Viagra'

FDA panel backs Sprout Pharma's 'female Viagra'

The panel voted by 18 to 6 that the drug - called flibanserin - should be approved to treat hypoactive sexual desire disorder (HSDD) in pre-menopausal women, opening the door for a ... However, the committee said that given the intended use of the drug

Latest news

  • Lundbeck launches Brintellix in first EU market Lundbeck launches Brintellix in first EU market

    Clinical trial results suggest Brintellix is at least as effective as Lexapro in adult patients with major depressive disorders and is significantly less likely to cause sexual dysfunction, a common problem

  • Menarini to raise awareness of sexual dysfunction Menarini to raise awareness of sexual dysfunction

    The rugby player ambassadors of Menarini's sexual dysfunction campaign. Italian pharma company A. ... Menarini Farmaceutica Internazionale has launched a campaign to address poor awareness of sexual dysfunction in the UK.

  • Female sexual dysfunction therapy pipeline Female sexual dysfunction therapy pipeline

    Female sexual dysfunction (FSD) pertains to persistent or recurrent problems with sexual response or desire in women. ... Both physical and psychosocial factors may be implicated in sexual dysfunction, although the exact cause cannot always be identified.

  • Making a big splash

    Whether you are treating heart disease or sexual dysfunction, the biggest competitor we face is often doing nothing.

  • It's all in the detail

    Defined by specific diseases, eg, psoriasis, rheumatoid arthritis, erectile dysfunction, etc, these groups will often discuss the topic in an oblique way. ... For example, erectile dysfunction conversations are often around sexual self-confidence, which

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Acquisition - business unit. 1, 045. EndoCeutics/ AMAG Pharmaceuticals. Intraros (prasterone), non-oestrogen product for postmenopausal atrophic vaginitis (FDA approved), female sexual dysfunction (phase III).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics